At ESMO 2024, Amanda Nizam, MD, from the Cleveland Clinic and Jørgen Bjerggaard Jensen, MD, from Aarhus University discuss the TOMBOLA trial, assessing early post-cystectomy immunotherapy according to ctDNA status in muscle-invasive bladder cancer. Dr. Jensen highlights the single-arm trial design, details the trial’s use of ctDNA, and elaborates on how TOMBOLA fits into the larger context of other trials in bladder cancer. ...
Urothelial Carcinoma Diagnostics
Advertisement
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Drs. Gupta and Kohlmann discuss why comprehensive germline testing is crucial for accurate diagnosis and treatment of UTUC.
Dr. Sonpavde shares his thoughts on first-line therapy for aUC, including trials like CheckMate 274, AMBASSADOR, and NIAGRA.
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
WGS-based ctDNA detection offered a median lead time of 131 days over radiographic imaging.
Dr. Klümper highlights an analysis of NECTIN4 amplification as a biomarker for predicting response to EV in mUC treatment.
How can clinical tools like circulating tumor DNA inform bladder cancer treatment adjustments and transitions?
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Advertisement
Video Insights
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.